104 results about "Helminths" patented technology

The invention provides novel diamino-functionalised chalcone derivatives and analogues thereof. Use of the compounds, or compositions comprising them, as pharmaceutically active agents, in particular against bacterial and parasitic infections, is also disclosed. The invention further relates to a method for detecting inhibitory effects against e.g., bacteria, parasites, fungi, and helminths. The chalcones of the invention carry amino substituents and exhibit enhanced biological effects combined with improved metabolic and physicochemical properties, making the compounds useful as drug substances, in particular as antiparasitic and bacteriostatic agents.

A new association of pesticides with synergic activity against insects, arachnida and worms.

The present invention provides a compound comprising a helminth-derived glycan and / or glycoconjugate thereof (e.g., a compound comprising a Lewisx antigen (e.g., LNFPIII), a non-Lewisx antigen (e.g., LNnT, LDN, and LDN derivatives), or a mixture of Lewisx and non-Lewisx antigens (e.g., SEA)), useful as a therapeutic compound for treating or preventing diseases associated with fat accumulation in the liver. The compounds of the invention are useful for treating or preventing the development of a fatty liver disease in a subject that has the disease or is at risk of developing the disease, and inhibiting lipogenesis in hepatocytes.; The invention also provides methods of regulating the Erk-c-fos / AP-1-FXRalpha signalling pathway by administering a compound comprising a helminth-derived glycan and / or glycoconjugate thereof to a subject with a fatty liver disease, or contacting a hepatocyte with a compound comprising a helminth-derived glycan and / or glycoconjugate thereof.

A method and apparatus optimizes the protection of computing networks. This protection utilizes attenuated (weakened) strains of live, replicating, malicious code such as viruses and worms, analogous to the development of live, attenuated, human vaccines in the medical field. In a preferred embodiment, this is achieved by (1) attenuating a malicious program, e.g. a virus or worm, or software vulnerability by limiting its virulence, i.e., limiting its damage and resource usage, (2) modifying the virus to confer immunity on the network that it infects, e.g., automatically patching a vulnerability, or marking the infected host as immune to further infection, (3) releasing the newly attenuated virus into the network, (4) tracking the attenuated virus and its success rate (e.g., rate and ratio of successfully patched to un-patched vulnerable hosts), and (5) limiting the spread of the virus vaccine, e.g., emergency termination, timeout to die, “white-list” of hosts not to touch, network IP address limitation, restricted IP ranges, variable address selection algorithm.

This invention provides a high throughput survival assay, using uptake of a marker dye (e.g. a fluorescent dye) as a marker of death of a nematode. The assay permits high throughput screening of thousands of compounds possible. By the application of automated worm handling technology we are able to accurately dispense nematodes into 384 well microtitre plates, at rates many thousand of times faster than previously possible. In addition, we have automated the analysis of survival by the use of a fluorometric plate reader that quantitates the degree of fluorescence within each well.